[{"address1": "5 Science Park", "address2": "395 Winchester Avenue", "city": "New Haven", "state": "CT", "zip": "06511", "country": "United States", "phone": "203 535 1456", "website": "https://www.arvinas.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.", "fullTimeEmployees": 445, "companyOfficers": [{"maxAge": 1, "name": "Dr. John G. Houston Ph.D.", "age": 63, "title": "Chairperson, CEO & President", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1144497, "exercisedValue": 0, "unexercisedValue": 12278804}, {"maxAge": 1, "name": "Mr. David K. Loomis M.B.A.", "age": 49, "title": "VP & Chief Accounting Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John P. Northcott", "age": 45, "title": "Chief Commercial Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Sinclair", "title": "Senior Vice President of Corporate Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul  McInulty", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander A. Santini", "age": 64, "title": "Senior Vice President of Global & U.S. Market Access", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Page", "title": "Senior VP & Global Head of Oncology Strategy and Program Leadership", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Masson Pharm.D.", "title": "Senior Vice President of Early Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Janet  Wang Ph.D.", "title": "VP & Head of Translational Sciences, Oncology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michelle  Edwards Pharm.D.", "title": "Vice President & Head of Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 24.82, "open": 24.79, "dayLow": 24.01, "dayHigh": 25.35, "regularMarketPreviousClose": 24.82, "regularMarketOpen": 24.79, "regularMarketDayLow": 24.01, "regularMarketDayHigh": 25.35, "beta": 1.982, "forwardPE": -5.5240173, "volume": 790341, "regularMarketVolume": 790341, "averageVolume": 697493, "averageVolume10days": 690030, "averageDailyVolume10Day": 690030, "bid": 25.28, "ask": 25.41, "bidSize": 100, "askSize": 200, "marketCap": 1731327104, "fiftyTwoWeekLow": 13.57, "fiftyTwoWeekHigh": 53.08, "priceToSalesTrailing12Months": 24.282288, "fiftyDayAverage": 31.7048, "twoHundredDayAverage": 32.25805, "currency": "USD", "enterpriseValue": 564626816, "floatShares": 56901802, "sharesOutstanding": 68431904, "sharesShort": 8925959, "sharesShortPriorMonth": 8942369, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1304, "heldPercentInsiders": 0.07079, "heldPercentInstitutions": 1.02587, "shortRatio": 13.5, "shortPercentOfFloat": 0.1328, "impliedSharesOutstanding": 68431904, "bookValue": 8.927, "priceToBook": 2.8340988, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -354800000, "trailingEps": -6.05, "forwardEps": -4.58, "pegRatio": 0.2, "enterpriseToRevenue": 7.919, "enterpriseToEbitda": -1.439, "52WeekChange": -0.006674528, "SandP52WeekChange": 0.2586832, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARVN", "underlyingSymbol": "ARVN", "shortName": "Arvinas, Inc.", "longName": "Arvinas, Inc.", "firstTradeDateEpochUtc": 1538055000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5ab3d208-4f36-3880-916e-a34548e61b36", "messageBoardId": "finmb_243040896", "gmtOffSetMilliseconds": -14400000, "currentPrice": 25.3, "targetHighPrice": 110.0, "targetLowPrice": 38.0, "targetMeanPrice": 68.44, "targetMedianPrice": 66.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 18, "totalCash": 1169299968, "totalCashPerShare": 17.087, "ebitda": -392300000, "totalDebt": 2600000, "quickRatio": 4.885, "currentRatio": 4.943, "totalRevenue": 71300000, "debtToEquity": 0.426, "revenuePerShare": 1.186, "returnOnAssets": -0.20783001, "returnOnEquity": -0.63318, "freeCashflow": -210987504, "operatingCashflow": -354100000, "revenueGrowth": -0.222, "grossMargins": 1.0, "operatingMargins": -3.29249, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-21"}]